OncoTherapy Science, Inc.

OncoTherapy Science, Inc. is a Japanese biotechnology company engaged in research and development of antibody drugs, cancer genome analysis, liquid biopsy, and new immunotherapies. Its pipeline includes OTS167, a small molecule maternal embryonic leucine zipper kinase inhibitor in Phase I/II trials for acute myeloid leukemia and Phase I trials for breast cancer, and OTS964, a small molecule TOPK inhibitor in non-clinical stage. The company also develops cancer peptide vaccines such as S-588410 (Phase III completed for esophageal cancer; Phase II for bladder cancer), S-488210 (Phase I/II for head and neck cancer), S-588210 (Phase I for solid tumors), and OTSGC-A24 (Phase I for gastric cancer), as well as antibody drugs including OTSA101 (Phase I for synovial sarcoma) and an anti-amyloid beta peptide antibody (Phase I completed for Alzheimer's disease). Incorporated in 2001, it is headquartered in Kawasaki, Japan.